Key result
Somatic mutations acquired in the months after SARS-CoV-2 infection endowed antibodies with greater neutralization potency, breadth, and resilience to viral escape mutations.
Why the study?
To determine the effects of somatic mutation on the properties of SARS-CoV-2 spike receptor-binding domain-specific antibodies.
Does somatic mutation improve the potency, breadth, and resilience of SARS-CoV-2 neutralizing antibodies against viral escape?
Does somatic mutation improve the potency, breadth, and resilience of SARS-CoV-2 neutralizing antibodies against viral escape?
Somatic mutation of SARS-CoV-2 neutralizing antibodies increases their potency, breadth, and resilience to viral escape mutations, suggesting prolonged antigen exposure may improve protection against variants.
Answers are grounded in this paper and cite their sources.
Supports affinity-matured antibody development for broader sarbecovirus protection; hypothesis-generating and requires human validation before clinical consideration.
Antibodies elicited in response to infection undergo somatic mutation in germinal centers that can result in higher affinity for the cognate antigen. To determine the effects of somatic mutation on the properties of SARS-CoV-2 spike receptor-binding domain (RBD)-specific antibodies, we analyzed six independent antibody lineages. As well as increased neutralization potency, antibody evolution changed pathways for acquisition of resistance and, in some cases, restricted the range of neutralization escape options. For some antibodies, maturation apparently imposed a requirement for multiple spike mutations to enable escape. For certain antibody lineages, maturation enabled neutralization of circulating SARS-CoV-2 variants of concern and heterologous sarbecoviruses. Antibody-antigen structures revealed that these properties resulted from substitutions that allowed additional variability at the interface with the RBD. These findings suggest that increasing antibody diversity through prolonged or repeated antigen exposure may improve protection against diversifying SARS-CoV-2 populations, and perhaps against other pandemic threat coronaviruses.
No takes yet. Share an insight, caveat, or question.
Muecksch et al. (2021) studied SARS-CoV-2 infection. Antibody maturation over time (6.2 months post-infection) vs. Early convalescent antibodies (1.3 months post-infection) was evaluated on Neutralization potency, breadth, and resilience to viral escape mutations. Somatic mutations acquired in the months after SARS-CoV-2 infection endowed antibodies with greater neutralization potency, breadth, and resilience to viral escape mutations.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: